Jaguar Health (JAGX) announced that on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel has granted Jaguar an extension through May 15, 2026, to demonstrate compliance with the $1.00 bid price rule for continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before May 15, 2026. The Panel may defer a compliance determination for up to 20 business days.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Health reports acceptance of abstracts on crofelemer for ESPGHAN meeting
- Jaguar Health Shareholders Approve Key Capital Structure Changes
- Jaguar Health plans to U.S. AI platform to enhance crofelemer program objectives
- Jaguar Animal Health Regains Nasdaq Compliance Through Capital Infusions
- Jaguar Health completes effectiveness study of crofelemer tablets